RESEARCH AND DEVELOPMENT OF A BIOSIMILAR DRUG BASED ON THE MONOCLONAL ANTIBODY ADALIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (Q3163420)
Jump to navigation
Jump to search
Project Q3163420 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | RESEARCH AND DEVELOPMENT OF A BIOSIMILAR DRUG BASED ON THE MONOCLONAL ANTIBODY ADALIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
Project Q3163420 in Spain |
Statements
1,223,176.5 Euro
0 references
2,446,353.0 Euro
0 references
50.0 percent
0 references
30 November 2015
0 references
31 December 2017
0 references
GH GENHELIX SOCIEDAD ANONIMA
0 references
42°38'2.94"N, 5°58'17.11"W
0 references
24089
0 references
Genhelix, SA, empresa perteneciente a Mabxience (iniciativa biotecnológica del grupo Chemo), a través del proyecto “Investigación y desarrollo de un medicamento biosimilar basado en el anticuerpo monoclonal Adalimumab para el tratamiento de la Artritis Reumatoide”, tiene como objetivo el desarrollo de un biosimilar de Adalimumab que cumpla con los requisitos establecidos por las agencias regulatorias y que introduzca mejoras sustanciales en la formulación del medicamento, en la producción (a través de una optimización de los medios de cultivo y escalado industrial), de tal manera que sea posible alcanzar un biosimilar con un precio final inferior al 50% del actual y por lo tanto una reducción en el coste del tratamiento, facilitando su uso en los países en vías de desarrollo. (Spanish)
0 references
Genhelix, SA, a company belonging to Mabxience (the Chemo Group biotechnology initiative), through the project “Research and development of a biosimilar drug based on the Adalimumab monoclonal antibody for the treatment of Rheumatoid Arthritis”, aims to develop an Adalimumab biosimilar that meets the requirements established by the regulatory agencies and which introduces substantial improvements in the formulation of the medicinal product, in production (through optimisation of the means of cultivation and industrial scaling), in such a way that it is possible to achieve a biosimilar with a final price of less than 50 % of the current price and thus a reduction in the cost of treatment, facilitating its use in developing countries. (English)
12 October 2021
0 references
León
0 references
Identifiers
IDI-20160106
0 references